Significance of analyzing circulating plasma cells in multiple myeloma: differences from measuring minimal residual diseases in bone marrow

Leuk Lymphoma. 2022 Feb;63(2):487-490. doi: 10.1080/10428194.2021.1992765. Epub 2021 Nov 2.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow
  • Humans
  • Multiple Myeloma* / diagnosis
  • Neoplasm, Residual / diagnosis
  • Neoplastic Cells, Circulating*
  • Plasma Cells